Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EBIT: 2015-2024

Historic EBIT for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to -$251.2 million.

  • Editas Medicine's EBIT rose 62.62% to -$24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$198.8 million, marking a year-over-year increase of 12.99%. This contributed to the annual value of -$251.2 million for FY2024, which is 48.45% down from last year.
  • Per Editas Medicine's latest filing, its EBIT stood at -$251.2 million for FY2024, which was down 48.45% from -$169.2 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's EBIT ranged from a high of -$134.8 million in FY2020 and a low of -$251.2 million during FY2024.
  • Over the past 3 years, Editas Medicine's median EBIT value was -$225.9 million (recorded in 2022), while the average stood at -$215.4 million.
  • In the last 5 years, Editas Medicine's EBIT grew by 25.12% in 2023 and then slumped by 48.45% in 2024.
  • Over the past 5 years, Editas Medicine's EBIT (Yearly) stood at -$134.8 million in 2020, then slumped by 43.24% to -$193.1 million in 2021, then declined by 16.98% to -$225.9 million in 2022, then increased by 25.12% to -$169.2 million in 2023, then plummeted by 48.45% to -$251.2 million in 2024.